Druggable Targets in Cytokine Release Syndromes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37656058.
- Also identified by DOI 10.1158/1078-0432.CCR-23-1975.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bispecific T-cell engagers and chimeric antigen receptor T cells share the problem of eliciting acute systemic inflammation episodes known as cytokine release syndrome. Knowledge on the sequential waves of cytokines that can be neutralized with clinically available agents is crucial to prevent or treat this condition without jeopardizing the antitumor therapeutic outcome. See related article by Leclercq-Cohen et al., p. 4449.
Medical subject headings
- Cytokine Release Syndrome
- Antibodies, Bispecific